| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/04/2001 | US6284240 Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| 09/04/2001 | US6284239 Murine model for human carcinoma |
| 09/04/2001 | US6282837 Methods of controlling the growth of undesired vegetation with herbicide tolerant plants or plant seeds having altered protoporphyrinogen oxidase activity |
| 08/30/2001 | WO2001063295A2 Dpi-6, a therapeutic biomarker in neurological disorders |
| 08/30/2001 | WO2001063290A1 Bcmp-7 as marker for diagnosis of breast cancer |
| 08/30/2001 | WO2001063289A1 Diagnosis of breast cancer using bcmp-11 as marker |
| 08/30/2001 | WO2001063288A1 Diagnosis of breast cancer using bcmp-81 as marker |
| 08/30/2001 | WO2001063279A2 Method of identifying toxic agents using differential gene expression |
| 08/30/2001 | WO2001062973A1 Antisense modulation of e2f transcription factor 3 expression |
| 08/30/2001 | WO2001062954A2 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 08/30/2001 | WO2001062942A2 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 08/30/2001 | WO2001062937A1 Skin infection-related retroviral sequences |
| 08/30/2001 | WO2001062936A2 Bunyaviridal reaper proteins and uses therefor |
| 08/30/2001 | WO2001062933A2 Muteins of interleukin-13 (il-13) |
| 08/30/2001 | WO2001062928A2 Polypeptides and nucleic acids encoding same |
| 08/30/2001 | WO2001062924A2 Human g protein-coupled receptors |
| 08/30/2001 | WO2001062920A2 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | WO2001062914A1 Bcmp 84, a protein associated to breast cancer |
| 08/30/2001 | WO2001062913A1 Vertebrate globin |
| 08/30/2001 | WO2001062912A2 Method of modulating glycosylation pathways |
| 08/30/2001 | WO2001062904A1 Regulation of human gelatinase b-like enzyme 1 |
| 08/30/2001 | WO2001062901A2 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | WO2001062897A1 Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines |
| 08/30/2001 | WO2001062893A2 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 08/30/2001 | WO2001062796A1 Ccr2-64i, polymorphic variant of the human ccrs receptor and its use in the diagnostic and treatment of atherosclerosis |
| 08/30/2001 | WO2001062795A1 COMPOUNDS RELATED TO OR DERIVED FROM GFRα4 AND THEIR USE |
| 08/30/2001 | WO2001062792A2 Cancer treatment and prognosis involving hes-1 protein |
| 08/30/2001 | WO2001062791A2 Control of tgf (beta) signaling by km23 superfamily members |
| 08/30/2001 | WO2001062790A2 Nuclear factor polypeptides and nucleic acids encoding same |
| 08/30/2001 | WO2001062789A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | WO2001062786A2 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | WO2001062784A2 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | WO2001062780A1 Gene expression system based on chimeric receptors |
| 08/30/2001 | WO2001062778A2 Tumour-specific animal proteins |
| 08/30/2001 | WO2001062725A2 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | WO2001062286A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | WO2001062285A1 Use of il-18 inhibitors |
| 08/30/2001 | WO2001062284A2 Novel method for down-regulation of amyloid |
| 08/30/2001 | WO2001062279A1 Method of treatment of anorectal disorders |
| 08/30/2001 | WO2001062271A1 Compositions and methods for the early diagnosis of ovarian cancer |
| 08/30/2001 | WO2001062228A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | WO2001062207A2 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 08/30/2001 | WO2001025248A3 Design of high affinity rnase h recruiting oligonucleotide |
| 08/30/2001 | WO2001016335A3 Stromelysin-homologous novel mmp-27 matrix metalloproteinase |
| 08/30/2001 | WO2001012806A3 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 08/30/2001 | WO2001012236A3 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 08/30/2001 | WO2001009325A3 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 08/30/2001 | WO2001008702A3 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 08/30/2001 | WO2001008696A3 Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
| 08/30/2001 | WO2001002540A3 Adenoviral vectors for treating disease |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |
| 08/30/2001 | US20010018445 Thalidomide |
| 08/30/2001 | US20010018427 Anticholesterol agent |
| 08/30/2001 | US20010018426 Lithium chloride |
| 08/30/2001 | US20010018203 DNA construction: promoter, recombinase recogniton sequence, drug resistance gene, polyA addition signal, recombinase recognition signal, virus structural protein gene, polyA addition signal, in that order |
| 08/30/2001 | US20010018202 Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells |
| 08/30/2001 | US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 08/30/2001 | US20010018058 Isolated polypeptide comprising an immunogenic portion of a breast protein comprising an amino acid sequence encoded by a polynucleotide |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2401219A1 Vertebrate globin |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401070A1 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | CA2401031A1 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| 08/30/2001 | CA2400842A1 Novel compounds |
| 08/30/2001 | CA2400838A1 Novel method for down-regulation of amyloid |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400544A1 Method of modulating glycosylation pathways |
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399550A1 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2397705A1 Compounds related to or derived from gfr.alpha.4 and their use |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/29/2001 | EP1127893A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127576A1 Uses of NM23-polypeptides in skin and intestinal disorders |
| 08/29/2001 | EP1127152A1 A method of recombination and agents useful for same |
| 08/29/2001 | EP1127151A2 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 08/29/2001 | EP1127150A2 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 08/29/2001 | EP1127149A2 Cells for the production of helper dependent adenoviral vectors |
| 08/29/2001 | EP1127140A2 Fk506-based regulation of biological events |
| 08/29/2001 | EP1127136A1 Delivery of superoxide dismutase to neuronal cells |
| 08/29/2001 | EP1127133A2 Polypeptide mediating cell permeability |
| 08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
| 08/29/2001 | EP1127121A2 Construction of retrovirus with the streptomyces mel locus expressible in mammalian cells |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 08/29/2001 | EP1127075A2 A method of treating tumors using fas-induced apoptosis |
| 08/29/2001 | EP1127070A2 $i(IKAROS) ISOFORMS AND MUTANTS |
| 08/29/2001 | EP1127068A1 Immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 08/29/2001 | EP1127064A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 08/29/2001 | EP1126879A1 Gene therapy for regulating smooth muscle cell tone |
| 08/29/2001 | EP1126873A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| 08/29/2001 | EP1126870A2 Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| 08/29/2001 | EP1126869A2 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| 08/29/2001 | EP1126866A2 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 08/29/2001 | EP1126858A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |